Literature DB >> 10729171

An antiviral compound that blocks structural transitions of poliovirus prevents receptor binding at low temperatures.

A W Dove1, V R Racaniello.   

Abstract

Drugs such as WIN51711 that inhibit picornavirus replication are thought to block poliovirus infectivity by binding to the capsid and preventing structural transitions required for uncoating. We examined the activity of WIN51711 at temperatures where capsid flexibility is thought to be decreased. Below 37 degrees C, WIN51711 inhibits the binding of wild-type poliovirus to cells but does not affect the binding of a poliovirus mutant which is believed to undergo structural transitions more readily. These results suggest that the poliovirus capsid must undergo structural changes to bind to its cellular receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729171      PMCID: PMC111905          DOI: 10.1128/jvi.74.8.3929-3931.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  Inhibition of poliovirus uncoating by disoxaril (WIN 51711).

Authors:  H Zeichhardt; M J Otto; M A McKinlay; P Willingmann; K O Habermehl
Journal:  Virology       Date:  1987-09       Impact factor: 3.616

2.  A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids.

Authors:  B Rombaut; K Andries; A Boeyé
Journal:  J Gen Virol       Date:  1991-09       Impact factor: 3.891

3.  Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding.

Authors:  C E Fricks; J M Hogle
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

4.  Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily.

Authors:  C L Mendelsohn; E Wimmer; V R Racaniello
Journal:  Cell       Date:  1989-03-10       Impact factor: 41.582

5.  Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug.

Authors:  M P Fox; M J Otto; M A McKinlay
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

6.  WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present.

Authors:  A G Mosser; R R Rueckert
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

7.  A comparison of the anti-rhinoviral drug binding pocket in HRV14 and HRV1A.

Authors:  K H Kim; P Willingmann; Z X Gong; M J Kremer; M S Chapman; I Minor; M A Oliveira; M G Rossmann; K Andries; G D Diana
Journal:  J Mol Biol       Date:  1993-03-05       Impact factor: 5.469

8.  Human rhinovirus 14 complexed with antiviral compound R 61837.

Authors:  M S Chapman; I Minor; M G Rossmann; G D Diana; K Andries
Journal:  J Mol Biol       Date:  1991-02-05       Impact factor: 5.469

9.  Antiviral agent blocks breathing of the common cold virus.

Authors:  J K Lewis; B Bothner; T J Smith; G Siuzdak
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

10.  In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug.

Authors:  M J Otto; M P Fox; M J Fancher; M F Kuhrt; G D Diana; M A McKinlay
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

View more
  10 in total

1.  Kinetic analysis of the effect of poliovirus receptor on viral uncoating: the receptor as a catalyst.

Authors:  S K Tsang; B M McDermott; V R Racaniello; J M Hogle
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Nectin-like interactions between poliovirus and its receptor trigger conformational changes associated with cell entry.

Authors:  Mike Strauss; David J Filman; David M Belnap; Naiqian Cheng; Roane T Noel; James M Hogle
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

3.  Kinetic models for receptor-catalyzed conversion of coxsackievirus B3 to A-particles.

Authors:  Steven D Carson
Journal:  J Virol       Date:  2014-07-30       Impact factor: 5.103

4.  Mechanism of action and capsid-stabilizing properties of VHHs with an in vitro antipolioviral activity.

Authors:  Lise Schotte; Mike Strauss; Bert Thys; Hadewych Halewyck; David J Filman; Mihnea Bostina; James M Hogle; Bart Rombaut
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

5.  Molecular epidemiology of Echovirus 30 in Taiwan, 1988-2008.

Authors:  Guan-Ming Ke; Kuei-Hsiang Lin; Po-Liang Lu; Yi-Chin Tung; Chu-Feng Wang; Liang-Yin Ke; Min-Sheng Lee; Pei-Chin Lin; Hui-Ju Su; Yi-Ying Lin; Tzu-Ping Huang; Jen-Ren Wang; Sheng-Yu Wang; Li-Ching Hsu; Pei-Yu Chu
Journal:  Virus Genes       Date:  2011-01-08       Impact factor: 2.332

6.  Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone.

Authors:  Shin-Ru Shih; Mun-Chung Tsai; Sung-Nien Tseng; Kuo-Fang Won; Kak-Shan Shia; Wen-Tai Li; Jyh-Haur Chern; Guang-Wu Chen; Chung-Chi Lee; Yen-Chun Lee; Kuan-Chang Peng; Yu-Sheng Chao
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Enterovirus 70 receptor utilization is controlled by capsid residues that also regulate host range and cytopathogenicity.

Authors:  Melissa Stewart Kim; Vincent R Racaniello
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

8.  Five of Five VHHs Neutralizing Poliovirus Bind the Receptor-Binding Site.

Authors:  Mike Strauss; Lise Schotte; Bert Thys; David J Filman; James M Hogle
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

9.  Dominant drug targets suppress the emergence of antiviral resistance.

Authors:  Elizabeth J Tanner; Hong-mei Liu; M Steven Oberste; Mark Pallansch; Marc S Collett; Karla Kirkegaard
Journal:  Elife       Date:  2014-11-03       Impact factor: 8.140

10.  The Broad-Spectrum Antiviral Potential of the Amphibian Peptide AR-23.

Authors:  Annalisa Chianese; Carla Zannella; Alessandra Monti; Anna De Filippis; Nunzianna Doti; Gianluigi Franci; Massimiliano Galdiero
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.